Topic Archives: Vitaliy Katsenelson

Comments

  • JohnM

    Thin-skinned with anger issues, yes. Don't know what "man-child" means. Con artist? No way. I've been investing in biote...

  • Avatar

    $DNLI Any thoughts in here about Denali? I've been following it for a year or so waiting for the IPO. I always loved Gen...

  • Avatar

    $ HALO LONG Halozyme Therapeutics (HALO) announces the initiation of a multi-arm clinical trial evaluating PEGPH20,...

  • SoGiAm

    $MRK & much more... NEW http://e.endpointsnews.com/t/ViewEmail/t/A537ED71EDB429B5/2F80028A944F69C925D77A725F39070E...

  • JohnM

    $best bio CEOs - I would LOVE to have you start a discussion on this topic. I've been investing in biotech since the Gen...

  • Avatar

    I too missed the Dr. exiting..I did call the firm and they do have a back up plan just in case it is needed..the managem...

  • Avatar

    I can't share any experience with that particular newsletter (I despise $1500/year newsletters in general), but I can sh...

  • Michael Jorrin,

    From what I have read, Genentech is only now launching a Phase 1 study in their DLK inhibitor, GDC-0134. I have the ut...

  • Avatar

    I wrote today about a different Alzheimer's Disease drug being tested in mice, not the one Doc Gumshoe mentioned. It als...

  • SoGiAm

    $AXSM long - Axsome Therapeutics Appoints Myrtle Potter to its Board of Directors http://phx.corporate-ir.net/phoenix...

  • JohnM

    $TGTX long, Genentech needs to protect $7 billion a year in Rituxan sales. It's bigger for them than Avastin. They can b...

  • Avatar

    $reph and $xene question/clarification; $reph has successfully completed both ph 3's and safety study, and will be s...

  • Avatar

    Thanks for kind words, I feel like a rat for doing it but I am going to send you an email, please ignore as you like wri...

  • Avatar

    Doc, jking and fellow Gummies: Fovista is dead. Final analysis of the two completed pivotal phase 3 studies of fovi...

  • Avatar

    Doc, there is another name that Rodman and Renshaw is also bullish on and you have made both positive and negative comme...

  • Avatar

    Genentech oncology head jumps ship to Bellicum as CEO: https://t.co/4r0RqVu2uM...

  • JohnM

    Andrew L. Salzman, M.D., Chief Executive Officer and Chief Medical Officer Dr. Salzman is a physician, scientist, inven...

  • Avatar

    Like this spot to enter IMDZ here after recent secondary. Doc if I recall you liked IMDZ platforms when we discussed th...

  • SoGiAm

    $BLRX today announced collaboration with Genentech, Phase 1b BL-8040 in combination with Atezolizumab, Genentech's anti...

  • Avatar

    Doc Kss, would you think this company Epic Science would be in direct competition with BIOC ? They have a impressive cli...

  • SoGiAm

    TGIF 1 more day....please let's stay focused. $tril vol off the charts last 3 days on strength. Maybe Uncle Irv gives u...

  • Avatar

    Interesting Article Genentech's Trojan horse destroys cocooned Staphylococcus aureus http://davidusharauli.blogspot.c...

  • SoGiAm

    Antibody Engineering & Therapeutics 2015 http://www.ibclifesciences.com/AntibodyEng/overview.xml A couple of audio cli...

  • Avatar

    Xenon (XENE) achieves milestone with Genentech partnership. http://finance.yahoo.com/news/xenon-pharmaceuticals-achieve...

  • Avatar

    The Biotech Book Shelf? Are you kidding me? What a great idea for a thread, Anamorph! Thanks for your wonderful post...

  • Anamorph

    I know there are Gummies who, like me, find Dr KSS's essays as valuable for the intellectual stimulation they provide as...

  • Avatar

    Genentech brain trust leaves company. http://www.forbes.com/sites/matthewherper/2015/05/14/former-genentech-researchers...

  • JohnM

    DR. KSS - I have been investing in biotech since Genentech came public and have for all those years read thousands of pr...

  • Avatar

    XENE: Xenon Pharmaceuticals Appoints Dr. Richard H. Scheller to Its Board of Directors BURNABY, British Columbia, Ma...

  • Avatar

    Michael, I have never read such an excellent synopsis of the current state of oncology research in all that time and le...

  • DrKSSMDPhD

    To Joe Schelble: about Curis($CRIS). I could see this one running another 20- 25 percent from here over the near term. W...

  • DrKSSMDPhD

    I'd meant to comment during this past very busy week about Newlink Genetics ($NLNK). If you saw it spike mightily this w...

  • Avatar

    Has anyone mentioned Immunogen? Been in a slow steady decline with a reversal today. I don't see any news. Just looks...

  • Avatar

    I did some DD on the Solazyme website and looking at some existing SA articles--it is a very intriguing story. The alga...

  • Avatar

    Thanks Eyedoc for your great sleuthing on Avalanche Bio. I would like to add that the CEO of this company, Tom Chalberg...

  • Avatar

    Google's Calico makes some important hires. An attempt to develop anti-aging treatments. http://www.fiercebiotech.com...

  • Avatar

    Thanks, Dr.KSS. This is not surprising. I know that this might give GILD longs a mild bit of PAT, so let me give it a li...

  • Avatar

    Senesco Announces New CEO SNTI announced the appointment of Ronald A. Martell as chief executive officer at the 2014 ...

  • Steve M

    Perhaps this explains a bit of the interest: Agios brought Dr. Chris Bowden on board to oversee the company's clinica...

  • Avatar

    Did he tell what the Cancer drug he was pushing? Wonder if the company is Roche or Genentech?...

  • Avatar

    Bought SGEN at just over $12 a year ago. My wife is in the biotech field. Some highly regarded execs from Genentech are ...

  • Avatar

    I own shares of Sangamo Biosciences (SGMO). Sangamo is focused on the research and commercial development of engineered ...

  • We use cookies on this site to enhance your user experience. By clicking any link on this page you are giving your consent for us to set cookies.

    More Info